Despite IDH1 is a powerful prognostic marker to distinguish lower grade gliomas and secondary glioblastoma from primary glioblastoma [23–25], its potential role as a therapeutic target for gliomas has not yet been determined [26] and further understanding of IDH1 in tumor metabolism is essential [27, 28]. This evidence concerns the gene IDH1 and glioblastoma.